Recombinant Human KIR3DL2/CD158k Protein

重组人KIR3DL2/CD158k蛋白 | 重组人杀伤细胞免疫球蛋白样受体3DL2蛋白

killer cell immunoglobulin-like receptor 3DL2, CD158k, CL-5, KIR3DL2, NKAT-4, NKAT4, NKAT4A, NKAT4B, killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2, p140

rp184056-10μg

10μg

无动物源

≥80%(SDS-PAGE)

KIR3DL2 (also known as 3DL2, p140, CD158k) is a type I transmembrane protein of the p70 family of killer cell Ig-like receptors (KIR). KIR are expressed on CD56dim NK cells and T cell subsets where they participate in identifying normal and abnormal cells and regulating effector functions of the innate immune system. KIR are named for the number of Ig-like domains (2D or 3D) in the extracellular domain (ECD) and whether they have long or short (L, S) cytoplasmic tail. As with other inhibitory KIR, KIR3DL2 has two ITIM domains within its long tail. KIR3DL2 is diverse, with twelve alleles identified and as many as five single amino acid (aa) polymorphisms found in a single individual. Unlike most other KIR, gene transcripts of KIR3DL2 are expressed by all individuals. KIR3DL2 is present on the cell surface as a disulfide-linked homodimer of two 70 kDa, 434 aa subunits. KIR3DL2 has shown peptide-specific binding to some HLA-A antigens, including A3 and A11. It also binds the abnormally folded HLA-B27 homodimer found in spondylarthritides, but not the normal heterodimer of HLA-B27 with beta 2-microglobulin. NK and CD4+ T cells from patients with spondylarthritides show increased KIR3DL2+ expression and this may play a role in disease pathology. KIR3DL2 is also a marker for atypical mononuclear (Sezary) cells in the blood of patients with Sezary syndrome, an erythrodermic form of cutaneous T cell lymphoma. Human KIR3DL2 ECD shows 88 - 92% aa identity to KIR3DL2 of other primates. KIR receptors have no structural orthologs in non-primates, although mouse Ly-49 proteins are functional orthologs. KIR are highly related. The closest relative, KIR3DL1 shows 86% aa identity with KIR3DL2 within the ECD.

Testing in progress

重组表达

61.5 kDa

C-hFc

70.4-92.7 kDa, under reducing conditions

HEK293 Accession #: P43630 | HEK293

<1.0 EU/μg

人(Human)

22-339 aa

MSLTVVSMACVGFFLLQGAWPLMGGQDKPFLSARPSTVVPRGGHVALQCHYRRGFNNFMLYKEDRSHVPIFHGRIFQESFIMGPVTPAHAGTYRCRGSRPHSLTGWSAPSNPLVIMVTGNHRKPSLLAHPGPLLKSGETVILQCWSDVMFEHFFLHREGISEDPSRLVGQIHDGVSKANFSIGPLMPVLAGTYRCYGSVPHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVQAGENVTLSCSSWSSYDIYHLSREGEAHERRLRAVPKVNRTFQADFPLGPATHGGTYRCFGSFRALPCVWSNSSDPLLVSVTGNPSSSWPSPTEPSSKSGICRHLIEGRMDPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Yes

Yes